

ACURA PHARMACEUTICALS, INC

Form 8-K

July 27, 2012

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D. C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act Of 1934**

**July 27, 2012**

Date of Report (Date of earliest event reported)

**ACURA PHARMACEUTICALS, INC.**

(Exact Name of Registrant as Specified in Charter)

State of New York

**1-10113**

11-0853640

(State of Other Jurisdiction (Commission File Number) (I.R.S. Employer

of Incorporation)

Identification Number)

**616 N. North Court, Suite 120**

**Palatine, Illinois 60067**

(Address of principal executive offices) (Zip Code)

**(847) 705-7709**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))

**Item 8.01 Other Events**

On July 27, 2012 we issued a press release disclosing that Pfizer Inc. has provided notice of exercise of its right to terminate the license to three development-stage products using the Company's Aversion® Technology and return such products to us. The termination will become effective in 12 months under our License Agreement with a subsidiary of Pfizer. A fourth product utilizing our Aversion® Technology, OXECTA® (oxycodone hydrochloride) Tablets CII, is being commercialized by Pfizer and Pfizer will retain all rights and obligations relating to OXECTA® under the License Agreement. A copy of our press release is being furnished as Exhibit 99.1 hereto.

**Item 9.01 Financial Statements and Exhibits**

Exhibit Number Description

99.1 Press Release dated July 27, 2012 announcing Update on Aversion Products.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ACURA  
PHARMACEUTICALS,  
INC.

By: /s/ Peter A. Clemens  
Peter A. Clemens  
Senior Vice President  
& Chief Financial  
Officer

Date: July 27, 2012

**Exhibit Index**

Exhibit Number Description

99.1 Press Release dated July 27, 2012 announcing Update on Aversion Products.